Literature DB >> 17827825

Losartan preserves integrity of cardiac gap junctions and PGC-1 alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial infarction.

Cheuk-Kwan Sun1, Li-Teh Chang, Jiunn-Jye Sheu, Chi-Young Wang, Ali A Youssef, Chiung-Jen Wu, Sarah Chua, Hon-Kan Yip.   

Abstract

This study tests the hypothesis that peroxisome proliferator activated receptor-gamma coactivator 1alpha (PGC-1alpha) and the integrity of gap junctions (GJs) were suppressed and the number of apoptotic bodies was increased in remote viable areas of left ventricle following acute myocardial infarction (AMI), which can be reversed by losartan therapy. Open chest surgery was consecutively performed on 32 adult male Sprague-Dawley rats. These rats were classified into 4 groups (n = 8/each group): group I, AMI (by ligation of left coronary artery (LCA) without treatment); group II, AMI with losartan 20 mg/kg/day; group III, sham control (without LAD ligation); and group IV, sham control with losartan 20 mg/kg/day. Echocardiography was performed on day 1 prior to AMI and on day 14 just before the rats were to be sacrificed for cellular and molecular studies. The results showed that mRNA expression of PGC-1alpha, integrated area (microm(2)) of clustered connexin43 (Cx43) spots, and Cx43 GJs were substantially down-regulated and the number of apoptotic bodies was markedly increased in nontreated AMI rats compared with healthy control and losartan-treated AMI rats on day 14 following AMI (all values of P < 0.001). Additionally, day 14 left ventricular (LV) ejection fraction was significantly lower in nontreated AMI rats than in healthy control and losartan-treated AMI rats (all values of P < 0.0001). Down-regulation of GJs and PGC-1alpha gene expression and cellular death were frequently observed in remote viable areas of LV following AMI. Losartan therapy reversed the adverse effects of AMI and preserved LV function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827825     DOI: 10.1536/ihj.48.533

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  18 in total

Review 1.  Mitochondria in heart failure.

Authors:  Mariana G Rosca; Charles L Hoppel
Journal:  Cardiovasc Res       Date:  2010-07-28       Impact factor: 10.787

Review 2.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury.

Authors:  Nina Kaludercic; Andrea Carpi; Roberta Menabò; Fabio Di Lisa; Nazareno Paolocci
Journal:  Biochim Biophys Acta       Date:  2010-09-24

Review 3.  Exercise training, energy metabolism, and heart failure.

Authors:  Renée Ventura-Clapier
Journal:  Appl Physiol Nutr Metab       Date:  2009-06       Impact factor: 2.665

4.  Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat.

Authors:  Hung-I Lu; Meng-Shen Tong; Kuan-Hung Chen; Fan-Yen Lee; John Y Chiang; Sheng-Ying Chung; Pei-Hsun Sung; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

5.  Resveratrol and pterostilbene attenuated smokeless tobacco induced cardiovascular aberrations in estrogen deficient female rats.

Authors:  A Nirwane; A Majumdar
Journal:  Toxicol Res (Camb)       Date:  2016-08-03       Impact factor: 3.524

6.  Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration.

Authors:  Tadashi Yoshida; Sarah Galvez; Sumit Tiwari; Bashir M Rezk; Laura Semprun-Prieto; Yusuke Higashi; Sergiy Sukhanov; Zipora Yablonka-Reuveni; Patrice Delafontaine
Journal:  J Biol Chem       Date:  2013-07-06       Impact factor: 5.157

7.  Peroxisome proliferator-activated receptor-γ-coactivator 1α (PGC-1α) gene expression in chronic kidney disease patients on hemodialysis: relation to hemodialysis-related cardiovascular morbidity and mortality.

Authors:  Eman Tayae Elsayed; Rasha Adel Nassra; Yasmine Salah Naga
Journal:  Int Urol Nephrol       Date:  2017-05-26       Impact factor: 2.370

Review 8.  Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure.

Authors:  An M Van Berendoncks; Anne Garnier; Renée Ventura-Clapier; Viviane M Conraads
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 9.  Mitochondria as a therapeutic target in heart failure.

Authors:  Marina Bayeva; Mihai Gheorghiade; Hossein Ardehali
Journal:  J Am Coll Cardiol       Date:  2012-12-05       Impact factor: 24.094

10.  Apoptosis in cardiovascular diseases: mechanism and clinical implications.

Authors:  Nam-Ho Kim; Peter M Kang
Journal:  Korean Circ J       Date:  2010-07-26       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.